Legend Biotech Shares Move Higher After Bullish BMO Pitch
BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ: LEGN) with a price target of $77, and an Outperform rating.
The analyst says the company's recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy.
Related: EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy
Though the analyst expects a gradual increase in sales due to manufacturing limitations, in the long term, he sees a blockbuster opportunity for Carvykti as the leader in multiple myeloma CAR T therapies with peak sales of around $5.5 billion.
Legend and its collaborator Janssen, a unit of Johnson & Johnson (NYSE: JNJ), are working on expanding Carvykti's addressable population through approvals in earlier lines and Japan & China that will bolster additional growth.
The analyst also notes upcoming data readouts from earlier-line therapies that can drive short-term upside.
Price Action: LEGN shares are up 6.84% at $45.90 during the market session on the last check Friday.
Latest Ratings for LEGN
Date | Firm | Action | From | To |
|---|---|---|---|---|
Mar 2022 | Morgan Stanley | Maintains | Overweight | |
Jan 2022 | Morgan Stanley | Upgrades | Equal-Weight | Overweight |
Jan 2022 | Morgan Stanley | Downgrades | Overweight | Equal-Weight |
View More Analyst Ratings for LEGN
View the Latest Analyst Ratings
See more from Benzinga
BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock
Centene Lifts FY22 Guidance On Higher Medicaid Premiums; Increases Share Buyback
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
